Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 351 - 400 out of 109,029

Document Document Title
WO/2015/152813A1
The present invention relates to a novel gene expression system comprising : a) a first nucleotide sequence encoding a fusion polypeptide of: a1) a destabilizing domain (DD) based on DHFR, and a2) a GTPcyclohydrolase 1 (GCH1) polypeptide...  
WO/2015/144576A1
The present invention relates to the use of 1-(4-chlorophenyl)-4-(4-morpholinyl)-2,5-dihydro-1H-imidazol -2- one or a physiologically acceptable salt thereof in a method for treatment and/or prevention of one or more epileptic disorders ...  
WO/2015/144290A8
The invention provides novel substituted pyridyl piperidine compounds according to Formula (I) which are Wnt pathway inhibitors, their manufacture and use for the treatment of hyperproliferative diseases such as cancer, inflammatory or d...  
WO/2015/143548A1
There is described a method of reducing drug liking a subject comprising the step of administering to the subject an oral pharmaceutical composition comprising: (i) hydromorphone or a pharmaceutically acceptable salt thereof, and (ii) na...  
WO/2015/148465A1
This invention relates generally to the discovery of pyrazole compounds selective for the neurotensin receptor 2 (NTR2) and uses thereof.  
WO/2015/145322A1
The invention relates to compounds of Formula (I) wherein R1, R2, R3, R4 and R5 are as described in the description; to pharmaceutically acceptable salts thereof, and to the use of such compounds as medicaments, especially as modulators ...  
WO/2015/144598A1
The technology provided herein relates to the novel use of compounds for improving cognition, concentration capacity, learning capacity and/or memory retentiveness, in particularly for the treatment and/or prophylaxis of cognitive, conce...  
WO/2015/148975A1
The present disclosure is directed to compositions comprising bryostatin-1, and methods comprising administering a composition comprising bryostatin-1, to treat Niemann-Pick Type C in a subject in need thereof.  
WO/2015/143622A1
Provided is a medium for establishing neuroepithelial stem cells and a method and use thereof. The medium comprises a differentiation culture used for inducing pluripotent stem cells to differentiate into primary neuroepithelial stem cel...  
WO/2015/147742A1
The present invention provides a novel use of benzoic acid salt in the manufacture of a composition for preventing or treating dementia or mild cognitive impairment, particularly, for preventing or treating mild Alzheimer's disease or am...  
WO/2015/148120A1
The present invention provides methods and compositions for treating a neurodegeneration disease or retinal degenerative disease in a mammal comprising the use of mesenchymal stem cells expressing a therapeutic compound. The invention al...  
WO/2015/148487A1
Autistic Spectrum Disorders (ASD) are a group of developmental disorders including autistic disorder, Asperger disorder and pervasive developmental disorder not otherwise specified which may be treated by use of a galanthamine analog whe...  
WO/2015/147639A1
Deoxynojirimycin and deoxygalactonojirimycin derivatives according to the present invention are N-alkylated D-galacto, D-gluco- or L-ido- deoxynojirimycin with a linear methyloxypentyl group bearing various sidegroups and a non-fused bic...  
WO/2015/144290A1
The invention provides novel substituted pyridyl piperidine compounds according to Formula (I) which are Wnt pathway inhibitors, their manufacture and use for the treatment of hyperproliferative diseases such as cancer, inflammatory or d...  
WO/2015/146522A1
Provided is a natural-derived antiaging agent. The antiaging agent comprises as an active ingredient at least one member selected from the group consisting of imidazole dipeptides and metabolites thereof. Also provided is an agent for im...  
WO/2015/146844A1
Provided is a novel sleep quality improver. A sleep quality improver containing cells of Lactobacillus casei and/or a product produced by treating the cell as an active ingredient.  
WO/2015/149005A1
Methods and compositions for cell therapy using immune modulating peptides comprising a MANF family protein, or fragment thereof, as an adjuvant to improve replacement cell viability and integration. The methods and compositions can be u...  
WO/2015/143253A1
The present disclosure is directed to crystalline forms of oxymorphone hydrochloride and compositions comprising any of the crystalline forms of oxymorphone hydrochloride. Also provided are processes for the preparation of crystalline fo...  
WO/2015/140545A1
The present invention provides a combined therapy comprising the use of one or more omega -3 fatty acids and one or more B vitamins and for treating cognitive impairment, such cognitive impairment disorders include, especially but not ex...  
WO/2015/140265A1
The invention relates to a composition for using in the treatment and/or prevention of chemically induced neuropathies, said composition comprising at least one reversible centrally acting acetylcholinesterase inhibitor. The invention al...  
WO/2015/143201A2  
WO/2015/139139A1
Methods and products (e.g., gRNAs, recombinant fusion proteins, frataxin targeting systems, compositions and kits) are described for increasing frataxin expression/levels in a cell, as well as uses of such methods and products, for examp...  
WO/2015/143001A1
A dietary supplement includes comprising a therapeutic amount of astaxanthin derived from a synthetic or natural ester or diol, and at least one of a phospholipid, glycolipid, and sphingolipid, and formulated into an oral dosage form, wh...  
WO/2015/140793A1
The present invention provides methods for diagnosing multiple sclerosis (MS) and prediction of responsiveness to interferon treatment. In specific embodiments, the present invention provides a gene expression profile for the prediction ...  
WO/2015/142924A1
Multivalent cation compositions of partially desulfated heparins are presented. Multivalent cation compositions of the disclosure can be formulated at high concentrations. The compositions, processes for making the compositions, unit dos...  
WO/2015/142209A1
The present invention relates to water with deuterium content from 1 to 139 ppm for use in the dietary management of psychological distress and method of the dietary management of psychological distress comprising a step of administer...  
WO/2015/143447A3
Disclosed herein are methods and compositions for treating, ameliorating, and/or preventing Alzheimers disease in ApoE4-postitive patients using particular compounds and compositions thereof.  
WO/2015/140130A1
The present invention relates to a compound of formula (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein R1,R2,R3,L1,L2,L3,L4,L5 and n, have the same meaning as that defined in the claims and the d...  
WO/2015/140081A1
A compound of the formula (I) or a tautomeric isoform thereof wherein R1 is selected from the group consisting of halogen, nitro, lower alkyl sulfonyl, cyano, trifluromethyl lower alkyl, lower alkoxy, lower alkoxycarbonyl, carboxy, lower...  
WO/2015/139847A1
The present invention relates to a composition for use in an orally, or rectally, transdermally or nasally administered medicament, characterized in that it includes: (b) at least one compound of Formula (I) and (b) at least one permeati...  
WO/2015/139386A1
The present invention relates to Canagliflozin monohydrate and crystal form thereof. Compared with the prior art, the Canagliflozin monohydrate and crystal form has higher stability in water or an aqueous system, is more suitable for a w...  
WO/2015/142500A3
This invention relates to compositions containing combinations of a balanced PC composition and one or more cannabinoids, a natural or synthetic derivative thereof, or a salt thereof, and kits containing such combinations and methods of ...  
WO/2015/143379A1
Several embodiments disclosed herein relate to methods for calculating a dosing regimen that is tailored specifically to the genetic and metabolic profile of a particular patient. In some embodiments, the dosing regimen is related to adm...  
WO/2015/140559A1
This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds...  
WO/2015/140736A1
Embodiments of the invention relate to methods for the manufacture of a protein-bound cannabinoid, comprising: obtaining a cannabinoid or cannabis in a form selected from the group consisting of cannabis smoke, cannabis vapor, cannabinoi...  
WO/2015/140799A1
An active agent capable of reducing quinone reductase 2 activity, for use in improvement of cognition in a subject is provided. Such an active agent may be a nucleic acid molecule that reduces the gene expression level of quinone reducta...  
WO/2015/142714A1
The adaptor associated kinase 1 (AAK1) inhibitor 3-methyloxetan-3-yl-4-(3-(2-methoxypyridin-3-yl)pyrazolo[1,5 -a]pyrimidin-5-yl)piperazine-1-carboxylate: and pharmaceutically acceptable salts and solid forms thereof are disclosed. Compos...  
WO/2015/139638A1
Provided herein are the acid addition salts of the compound named (2S, 4S) -1- [2- [ [5-hydroxy-2-methyl-3, 3a, 4, 5, 6, 6a-hexahydro-1H-pentalen-2-yl] amino] acetyl] -4 -fluoro-pyrrolidine-2-carbonitrile, preparation methods and pharmac...  
WO/2015/142061A1
The present invention relates to a composition for treating inflammatory brain disease comprising stem-cell-derived exosome as an active ingredient. The stem-cell-derived exosome according to the present invention can advantageously be u...  
WO/2015/138917A1
Provided herein is a method of treating or preventing a disease or disorder (e.g., MS) in a subject in need thereof, comprising (a) administering to the subject a first dose of a pharmaceutical composition comprising a fumarate agent (e....  
WO/2015/136027A1
The invention relates to carbohydrate ligands presenting the minimal Human Natural Killer-1 (HNK-1) epitope that bind to anti-MAG (myelin-associated glycoprotein) IgM antibodies, and their use in diagnosis as well as for the treatment of...  
WO/2015/137499A3
 A hydrogen molecule-supplying exterior body (1) for producing a hydrogen-containing biological application solution, said hydrogen molecule-supplying exterior body (1) being provided with a water vapor-permeable container (12) in whic...  
WO/2015/135947A1
The present invention relates to piperazine phenothiazine derivatives useful as therapeutic agents for treating spasticity, particularly following an ischemia or traumatic injury, or compression syndrome. The invention further relates to...  
WO/2015/137419A1
[Problem] The purpose of the present invention is to activate abnormal mesenchymal stem cells that have experienced a loss or reduction in therapeutic efficacy, or that have a disease-exacerbating effect, and restore the cells to a condi...  
WO/2015/139056A1
Provided are combinations of homeopathic remedies to be used by persons inclined to addictive situations as well as methods for delivery of such preparations. The combination includes the nine remedies of Argentum Nitricum, Arsenicum Alb...  
WO/2015/136091A1
The present invention relates to tricyclic hexahydrodiazepinoquino lines carrying a substituted alkyl radical, to a method for producing them, to a pharmaceutical composition containing such compounds, to their use as modulators, especia...  
WO/2015/136247A1
The invention provides methods and materials for treating a seizure disorder such as epilepsy in a patient which employ a vector encoding a modified receptor, the so-called "DREADD" receptor being characterised by (i) a decreased respons...  
WO/2015/136253A1
The disclosure provides extended release pharmaceutical formulations comprising an opioid,particularly buprenorphine, a biocompatible organic solvent, and, optionally, a glycol, for use in the treatment of pain or opioid dependence. The ...  
WO/2015/136003A3
Disclosed is a pharmaceutical composition comprising i) a dopamine agonist and ii) a L-DOPA derivative in combination in form of a liquid preparation. The pharmaceutical composition is used for the treatment of Parkinson's disease, restl...  
WO/2015/137441A1
Provided is an anti-myristoylated protein antibody or antigen-binding fragment thereof, characterized by having a light-chain variable domain consisting of CDR-L1 comprising the amino acid sequence shown by Sequence No. 1, CDR-L2 compris...  

Matches 351 - 400 out of 109,029